2021 Company Highlights

2021 was full of activity at Cumberland – and we’re especially proud to share several significant developments from a year that presented its share of challenges.

Company and Product Updates

Although the COVID-19 pandemic continues to affect our lives and communities as we approach the end of 2021, we are optimistic as vaccination rates rise and case counts decline, and we remain fully operational while keeping our team safe and our facilities open.

Mid-Year Check In: COVID-19 and Product Line Updates

Though the COVID-19 pandemic endures, we at Cumberland Pharmaceuticals remain hopeful as vaccination rates continue to rise. We are carefully monitoring the situation so that we can act quickly, if necessary, to keep our employees safe and our business strong. 

Company Updates from Q1 2021 and Looking Ahead

The novel coronavirus continues to affect our lives over a year after its arrival in the United States. However, given several recent developments, we are hopeful for a brighter future: More than 100 million Americans have been fully vaccinated, new cases are declining, the weather is warming and an overall reopening of our country is underway.


Product Updates and Looking Forward


The coronavirus pandemic has made this a challenging year for everyone. Our thoughts are with the many who have suffered, especially those with resulting life-threatening conditions, and those who have lost their jobs or their businesses. Cumberland is grateful to be part of an industry that is playing a key role in fighting back.

Mid-Year Check In and COVID-19 Updates


As the world continues to adapt to a new way of life due to the COVID-19 pandemic, Cumberland continues to take action to protect our employees, secure our supply chain and support the patients who can benefit from our medicines. Our office is open and we continue to operate our business while maintaining compliance with the many laws and regulations we fall under.


Caldolor®, RediTrex® and COVID-19 Updates


As the novel coronavirus has swept across the country, we have noted the profound changes affecting the economy, health care, employment and our daily lives.

2019 Review and Looking Forward

2019 Review and Looking Forward

Last year began with a strategic review of our brands, capabilities and international partners, which ultimately led to a restructured product portfolio, a host of new international partnerships and an expansion of our corporate, sales and medical teams.

New Ready-to-Use Caldolor is Designed to Help Address National Opioid Crisis.


We are very pleased to announce that the national launch of our FDA-approved Next Generation Caldolor product!